Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Mexico - Delayed Quote MXN

NOVOB.MX,0P0001N6MI,0 (NOVOB.MX)

2,600.00

0.00

(0.00%)

At close: July 23 at 2:00:00 PM CST

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Investor's Business Daily 17 hours ago

NONOF

NVO

HIMS
Novavax reports large quarterly revenue declines, rethinks its strategic direction

Novavax closed up the day it reported a pivot in direction.

Yahoo Finance yesterday

SNY

SNYNF

NONOF
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 27 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by corresponde

GlobeNewswire yesterday

NONOF

NVO
Eli Lilly to build 4 more manufacturing sites in US

Eli Lilly announced it will increase its manufacturing capacity in the US.

Yahoo Finance 2 days ago

NONOF

NVO

LLY
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Yahoo Finance 3 days ago

HIMS

NONOF

NVO
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.

Investor's Business Daily 3 days ago

NVDA

AMZN

NONOF
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Investor's Business Daily 7 days ago

LLY

NONOF

NVO
CrowdStrike, Hims & Hers, Rivian: Market Minute

Seana Smith breaks down Friday's top stock market movers on Market Minute. CrowdStrike (CRWD) shares are sliding following news that both the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) are investigating its $32 million deal with Carahsoft to provide cybersecurity tools to the IRS. In the healthcare sector, Hims & Hers (HIMS) stock nosedives after the FDA announced an end to shortages of weight loss medications. This news is having the opposite effect on Novo Nordisk (NVO), whose shares are surging in response. Meanwhile, Rivian (RIVN) stock is dipping after the company provided weaker-than-expected delivery guidance, highlighting ongoing demand challenges in the electric vehicle (EV) market. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Angel Smith

Yahoo Finance Video 7 days ago

HIMS

RIVN

CRWD
Trending tickers: Alibaba, Tesla, Rivian, Novo Nordisk and Standard Chartered

The latest investor updates on stocks that are trending on Friday.

Yahoo Finance UK 7 days ago

BABA

BABAF

NSANF
Moderna's Q4 loss: Can the pharma giant get to profitability?

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight. Spikevax, the company's COVID-19 vaccine, managed to bring in $3.1 billion across 2024. "While there is the Merck (MRK) cancer vaccine, the Phase 3 CMV vaccine, and the norovirus vaccine, the CMV vaccine has been delayed. The data has not hit, and they sound like they're pushing it out to later this year," Yee says on the other vaccine projects Jefferies is "cautiously optimistic" on. Yee also comments on the tightening GLP-1 weight-loss drug race between Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 14 days ago

MRNA

AMGN

LLY
Hims & Hers stock sees another spike in trading days after Super Bowl ad

Retail investors are boosting Hims & Hers after the success of its Super Bowl ad Sunday.

Yahoo Finance 15 days ago

LLY

HIMS

NONOF
Novo Nordisk initiated by Morgan Stanley on equal weight coverage

Morgan Stanley (MS) initiated equal weight coverage on healthcare company Novo Nordisk (NVO), citing the potential in the global obesity market. While Novo's stock dropped slightly, the firm sees opportunities in obesity treatment but warns market expectations may be too high. Questions remain about pricing and government negotiations, affecting both Novo and its competitors, including Eli Lilly (LLY). Madison Mills and Seana Smith break down the details on Catalysts. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Josh Lynch

Yahoo Finance Video 16 days ago

NONOF

NVO
Why the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief

Investors have largely abandoned much of the healthcare space in favor of tech. But as tech falters, some strategists see the underrated sector as being the perfect tech hedge.

Yahoo Finance 16 days ago

IBB

NONOF

NVO
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. On Friday, Sen. Richard Durbin (D-Ill.) and Sen. Roger Marshall (R-Kan.) sent a letter to acting Food and Drug Administration Commissioner Sarah Brenner asking the agency to investigate Hims for "misleading patients."

Investor's Business Daily 21 days ago

NONOF

NVO

HIMS
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nor

GlobeNewswire 21 days ago

NONOF

NVO
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investig

GlobeNewswire 22 days ago

NONOF

NVO
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Investor's Business Daily 22 days ago

VKTX

NONOF

NVO
Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before tomorrow’s bell. Given recent price action, a buy-the-dip scenario could be on the cards. The company fumbled its previous earnings call, leading to a 6% drop in the stock late last year. With market performance set to return to equilibrium, LLY could be the low-hanging fruit speculators are looking for while also appealing to long-term value investors wh

TipRanks 23 days ago

LLY

NONOF

NVO
Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.

Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a fourth-quarter beat.

Investor's Business Daily 23 days ago

NONOF

NVO
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this year.

Yahoo Finance 23 days ago

NONOF

NVO

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NOVOB.MX,0P0001N6MI,0 (NOVOB.MX)

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Novavax reports large quarterly revenue declines, rethinks its strategic direction

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Eli Lilly to build 4 more manufacturing sites in US

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

CrowdStrike, Hims & Hers, Rivian: Market Minute

Trending tickers: Alibaba, Tesla, Rivian, Novo Nordisk and Standard Chartered

Moderna's Q4 loss: Can the pharma giant get to profitability?

Hims & Hers stock sees another spike in trading days after Super Bowl ad

Novo Nordisk initiated by Morgan Stanley on equal weight coverage

Why the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.

Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO